We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Ogt and Intelliseq Launch NGS Reporting and Interpretation for All Myeloid Malignancy Panels

The double helix structure of DNA.
Credit: iStock.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

OGT, A Sysmex Group Company, and Intelliseq, a genome informatics company, are delighted to announce the release of GeneSpect™ Somatic Reporter for use with OGT’s SureSeq™ portfolio of next generation sequencing (NGS) panels. This advanced analytical reporting solution pairs state-of-the-art variant interpretation and reporting with OGT’s class-leading NGS panels and bioinformatics solutions. Users of SureSeq Myeloid panels can now benefit from insightful tertiary reporting for all myeloid malignancy content and variants with the GeneSpect Somatic Reporter.


Powered by Intelliseq’s iFlow™ engine, GeneSpect Somatic Reporter presents genomic data and relevant clinical associations in an expert-informed format optimised for the needs of NGS reporting for haematological cancers. iFlow Engine integrates with OGT’s proprietary bioinformatics pipeline to generate clinically relevant variant interpretations, drug and therapy associations, clinical guidelines criteria and clinical trials associations for OGT customers. "NGS has the potential to provide significant insight into cancer research, and clinicians need help deciphering this data" states Adrian Smith, CEO of OGT. "The SureSeq platform partnered with the GeneSpect Somatic Reporter simplifies this critical step, ensuring users maximise the benefits of their NGS data to progress our understanding of cancer."

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

“GeneSpect’s myeloid reporting solution is the result of an amazing partnership that centres on both our companies’ desire to drive NGS clinical research solutions to the forefront,” says Klaudia Szklarczyk-Smolana, CEO of Intelliseq. “We’ve invested in not only our data infrastructure to enable the delivery of complex clinical insight, but we’ve also partnered with experts to understand the unique needs of providers when it comes to NGS testing in haematology. We are confident that our expert-informed report will save time for both labs and their clients, while still providing best-in-class information, from interpretations to clinical trials.”


In addition to the release of the GeneSpect Somatic Reporter for myeloid malignancies, Intelliseq and OGT also announce they will support reporting for all NGS disease areas offered in the SureSeq portfolio.  SureSeq users will also be able to avail themselves of Intelliseq’s fully customisable report template engine, Customica™ Builder which allows users to customise all aspects of the reporting process, from interpretation through to report rendering. 


GeneSpect Reports and Customica Builder will be presented at the upcoming 2023 Association for Molecular Pathology (AMP) annual meeting in Salt Lake City. OGT will also present data on its latest additional products for myeloid malignancies in a corporate workshop on November 15th, 1:00pm-1:50pm in room 251A, plus host expert sessions at booth #1423.